Medtech startup Robeauté, which specialises in developing neurosurgical microrobots, has raised US$28 million, led by Plural, Cherry Ventures, and Kindred Ventures.
Additional monetary support was provided by LocalGlobe, Think.Health, APEX Ventures, and Brainlab.
Read more: Mendaera closes US$73m Series B funding to scale robotics and AI across medical procedures
The funding will be used to continue the development of microrobot technology, with trials starting in 2026, and the setting up of US operations.
Robeauté’s microrobots are the size of a grain of rice, and can move through the extracellular matrix to reach multiple sites of interest to carry out a particular task. They differ from traditional neurosurgery methods using larger tools which can impede multi-site access.
Additionally, pharmaceutical treatments could struggle to make a significant enough impact, due to the complexities of crossing the blood-brain barrier to reach the needed area.
The company has said that its microrobot can embark on specific missions depending on the pathology of a particular disease. This allows the robot to deliver molecules, implant electrodes, (as might be the case to treat Parkinson’s), or collect cell data samples through sensors.
Bertrand Duplat, co-founder and CEO of Robeauté, said: “There is unexplored potential for microrobots in medicine. Current neurosurgery techniques are invasive and can be fatal, whilst it is difficult for treatment to pass the blood-brain barrier and get to its intended target.
“We’re creating microrobots that will bring unparalleled access to the brain with personalised, precision medicine that can transform treatments and patient outcomes.”
Join more than 11,000 industry leaders at Robotics and Automation Exhibition on 25-26 March 2025, at the NEC Birmignham to explore cutting-edge technologies, connect with peers and discover the latest innovations shaping the future of manufacturing, engineering and logistics. Register for free now to secure your place at this premier event!
